Full Text
PND35 Belgian Cost-Utility Analysis of Gilenya® (Fingolimod) in the Management of Adults with Active Relapsing Remitting Multiple Sclerosis

Abstract

Authors

S. Drieskens K. Moeremans

Back to Volume 14, Issue 7
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×